Rezolute, Inc.

Rezolute, Inc.

RZLTยทNASDAQ

$4.58

+14%
HealthcareBiotechnology

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$441.02M
EPS-0.9800
P/E Ratio-4.67
Earnings Date09/10/2026

No Dividend Yield Data

RZLT has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

RZLT has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

RZLT has not reported any net dividends paid values in the available annual periods.

Rezolute, Inc.

Rezolute, Inc. Dividend History

RZLT ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

RZLT Dividend Payment History

RZLT ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
rzlt

Rezolute, Inc. Payout Ratio Analysis

RZLT ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-74.41M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.